Nepicastat oralAlternative Names: DBH inhibitor programme; DβH inhibitor programme; Nepicastat hydrochloride; SYN-117
Latest Information Update: 02 Mar 2017
At a glance
- Originator Roche
- Developer Biotie Therapies Corp.
- Class Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
- Mechanism of Action Dopamine beta hydroxylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cocaine abuse; Parkinson's disease; Post-traumatic stress disorders